Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preservative-free latanoprost versus Xalatan in open-angle glaucoma or ocular hypertension
2017-002910-29Phase 3Completed
- Sponsor
- Pharmathen
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Pharmathen. Primary endpoint: Change in intraocular pressure at 8:00 am from baseline to week 12. Started Sep 2017; status: completed.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2017-002910-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002910-29.